Bulletin 61: Montelukast

Annual spend across the PrescQIPP for the leukotriene receptor antagonists montelukast and zafirlukast is almost £3million. This bulletin and supporting materials are aimed at ensuring prescribing of the leukotriene receptor antagonists is generic and also reviewing treatment to assess for continued need in line with the BTS/SIGN Asthma management guideline.

Loading...